|Position||Trades||Duration||Win rate||Win/loss||Avg win||Avg loss||Return|
|Position||Trades||Duration||Win Rate||Win/Loss||Avg Win||Avg Loss||Return|
Trading: SELL @ $0.18
Signal Strength: MEDIUM
Impedimed (ASX:IPD) currently has negative Volume MACD of -101210. This means the signal line is less than the Volume MACD line signalling a bearish movement.
Indicator can be used in isolation or in additional to another technical indicator to confirmation for trading entry. This indicator has the ability to detect the speed of movement & give an early signal for a potential movement. By understanding the rate at which the price is moving in respect to the stocks historical trades, enables positions to be set in place based on changes in the speed of movement
Volume Moving Average Convergence/Divergence (VMACD) is an indicator that shows the relationship between two moving averages. It is calculated as a difference between the fast and slow moving averages. The historically popular is the difference between a securities 26-day and 12-day Exponential Moving Averages (EMA).
Calculation: Moving Average Convergence Divergence Volume (VMACD):
1) VMACD Line: (12-day EMA - 26-day EMA);
2) Signal Line: 9-day EMA of VMACD Line;
3) VMACD Histogram: VMACD Line - Signal Line;
PROFILE: Impedimed (IPD.AX)
Stock Exchange: ASX
Ticker Codes: | IPD.AX | ASX:IPD |
ImpediMed Limited, together with its subsidiaries, engages in the development, manufacture, and sale of bioimpedance devices and consumables in Australia, North America, Europe, and internationally. The company operates through Medical and Test & Measurement segments. It offers L-Dex U400, a technology that utilizes the characteristics of frequency dependent current flow to quantify changes in extracellular fluid in the patient's limb; and SFB7, a tetra polar bioimpedance spectroscopy device that scans various frequencies for the estimation of body composition in healthy individuals. The company also provides DF50, a single frequency body composition analysis in healthy individuals; and ImpediVET, a bioimpedance spectroscopy technology for use in veterinary applications. Its products are used in a range of applications, such as in the assessment and monitoring of secondary lymphedema, as well as monitoring of body composition and hydration. In addition, the company is involved in the supply of power precision testing and measuring equipment. ImpediMed Limited was founded in 1999 and is headquartered in Pinkenba, Australia.
|ALK Alkane Exploration||0.71||11.9||5,930,185||-129,172||BEARISH|
|CVW Clearview Wealth||0.7||7.7||158,305||-9,410||BEARISH|
|MNS Milnes Holdings||0.17||6.3||123,862||-10,320||BEARISH|
|PME Pro Medicus||29.84||5.5||756,943||-15,216||BEARISH|
|DCN Dacian Gold||1.36||4.6||5,417,629||-115,248||BEARISH|
|RSG Resolute Mining||1.6||4.6||10,305,965||-333,348||BEARISH|